{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,15]],"date-time":"2026-09-15T22:45:15Z","timestamp":1789512315806,"version":"build-2803163510"},"reference-count":15,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2024,2,1]],"date-time":"2024-02-01T00:00:00Z","timestamp":1706745600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,2,1]],"date-time":"2024-02-01T00:00:00Z","timestamp":1706745600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,2,1]],"date-time":"2024-02-01T00:00:00Z","timestamp":1706745600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2024,2,1]],"date-time":"2024-02-01T00:00:00Z","timestamp":1706745600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2024,2,1]],"date-time":"2024-02-01T00:00:00Z","timestamp":1706745600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2024,2,1]],"date-time":"2024-02-01T00:00:00Z","timestamp":1706745600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2024,2,1]],"date-time":"2024-02-01T00:00:00Z","timestamp":1706745600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Bioorganic & Medicinal Chemistry Letters"],"published-print":{"date-parts":[[2024,2]]},"DOI":"10.1016\/j.bmcl.2024.129622","type":"journal-article","created":{"date-parts":[[2024,1,20]],"date-time":"2024-01-20T12:09:20Z","timestamp":1705752560000},"page":"129622","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":8,"special_numbering":"C","title":["Structure-based design and synthesis of sulfonylureas as novel NLRP3 inhibitors for Alzheimer\u2019s disease"],"prefix":"10.1016","volume":"99","author":[{"given":"Eun Young","family":"Kim","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jae Hong","family":"Im","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jinhe","family":"Han","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Won-Jea","family":"Cho","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"5","key":"10.1016\/j.bmcl.2024.129622_b0005","doi-asserted-by":"crossref","first-page":"404","DOI":"10.1038\/nri1843","article-title":"Immunology and immunotherapy of Alzheimer's disease [published correction appears in Nat Rev Immunol. 2006 Jun;6(6):490]","volume":"6","author":"Weiner","year":"2006","journal-title":"Nat Rev Immunol"},{"key":"10.1016\/j.bmcl.2024.129622_b0010","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1146\/annurev-med-052919-120219","article-title":"Novel targets for Alzheimer's disease: a view beyond amyloid","volume":"72","author":"Ray","year":"2021","journal-title":"Annu Rev Med"},{"key":"10.1016\/j.bmcl.2024.129622_b0015","doi-asserted-by":"crossref","unstructured":"Breijyeh Z, Karaman R. Comprehensive review on Alzheimer's disease: causes and treatment. Molecules 2020;25(24):5789. Published 2020 Dec 8. doi: 10.3390\/mol ecules25245789.","DOI":"10.3390\/molecules25245789"},{"issue":"10284","key":"10.1016\/j.bmcl.2024.129622_b0020","doi-asserted-by":"crossref","first-page":"1577","DOI":"10.1016\/S0140-6736(20)32205-4","article-title":"Alzheimer's disease","volume":"397","author":"Scheltens","year":"2021","journal-title":"Lancet"},{"issue":"3","key":"10.1016\/j.bmcl.2024.129622_b0025","doi-asserted-by":"crossref","first-page":"222","DOI":"10.1016\/S1474-4422(20)30440-3","article-title":"New insights into atypical Alzheimer's disease in the era of biomarkers","volume":"20","author":"Graff-Radford","year":"2021","journal-title":"Lancet Neurol"},{"issue":"9","key":"10.1016\/j.bmcl.2024.129622_b0030","doi-asserted-by":"crossref","first-page":"1205","DOI":"10.1038\/aps.2017.28","article-title":"Amyloid beta: structure, biology and structure-based therapeutic development","volume":"38","author":"Chen","year":"2017","journal-title":"Acta Pharmacol Sin"},{"issue":"7","key":"10.1016\/j.bmcl.2024.129622_b0035","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1038\/nri.2016.58","article-title":"Inflammasomes: mechanism of assembly, regulation and signalling","volume":"16","author":"Broz","year":"2016","journal-title":"Nat Rev Immunol"},{"issue":"8","key":"10.1016\/j.bmcl.2024.129622_b0040","doi-asserted-by":"crossref","first-page":"477","DOI":"10.1038\/s41577-019-0165-0","article-title":"The NLRP3 inflammasome: molecular activation and regulation to therapeutics","volume":"19","author":"Swanson","year":"2019","journal-title":"Nat Rev Immunol"},{"key":"10.1016\/j.bmcl.2024.129622_b0045","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2019.111822","article-title":"Development of small molecule inhibitors targeting NLRP3 inflammasome pathway for inflammatory diseases","volume":"185","author":"Zhang","year":"2020","journal-title":"Eur J Med Chem"},{"issue":"3","key":"10.1016\/j.bmcl.2024.129622_b0050","doi-asserted-by":"crossref","first-page":"248","DOI":"10.1038\/nm.3806","article-title":"A small-molecule inhibitor of the NLRP3 inflammasome for the treatment of inflammatory diseases","volume":"21","author":"Coll","year":"2015","journal-title":"Nat Med"},{"issue":"1","key":"10.1016\/j.bmcl.2024.129622_b0055","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1083\/jcb.200903124","article-title":"Glyburide inhibits the Cryopyrin\/Nalp3 inflammasome","volume":"187","author":"Lamkanfi","year":"2009","journal-title":"J Cell Biol"},{"issue":"11","key":"10.1016\/j.bmcl.2024.129622_b0060","doi-asserted-by":"crossref","first-page":"3219","DOI":"10.1084\/jem.20171419","article-title":"Identification of a selective and direct NLRP3 inhibitor to treat inflammatory disorders","volume":"214","author":"Jiang","year":"2017","journal-title":"J Exp Med"},{"issue":"13","key":"10.1016\/j.bmcl.2024.129622_b0065","doi-asserted-by":"crossref","first-page":"9792","DOI":"10.1074\/jbc.M109.082305","article-title":"Anti-inflammatory compounds parthenolide and Bay 11\u20137082 are direct inhibitors of the inflammasome","volume":"285","author":"Juliana","year":"2010","journal-title":"J Biol Chem"},{"key":"10.1016\/j.bmcl.2024.129622_b0070","article-title":"Chalcone: a potential scaffold for NLRP3 inflammasome inhibitors","volume":"7","author":"Thapa","year":"2023","journal-title":"Eur J Med Chem Rep."},{"key":"10.1016\/j.bmcl.2024.129622_b0075","doi-asserted-by":"crossref","unstructured":"Dekker C, Mattes H, Wright M, et al. Crystal structure of NLRP3 NACHT domain with an inhibitor defines mechanism of inflammasome inhibition. J Mol Biol 2021;433(24):16730 09. doi: 10.1016\/j.jmb.2021.167309.","DOI":"10.1016\/j.jmb.2021.167309"}],"container-title":["Bioorganic & Medicinal Chemistry Letters"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0960894X24000246?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0960894X24000246?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,18]],"date-time":"2025-10-18T07:50:13Z","timestamp":1760773813000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0960894X24000246"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,2]]},"references-count":15,"alternative-id":["S0960894X24000246"],"URL":"https:\/\/doi.org\/10.1016\/j.bmcl.2024.129622","relation":{},"ISSN":["0960-894X"],"issn-type":[{"value":"0960-894X","type":"print"}],"subject":[],"published":{"date-parts":[[2024,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Structure-based design and synthesis of sulfonylureas as novel NLRP3 inhibitors for Alzheimer\u2019s disease","name":"articletitle","label":"Article Title"},{"value":"Bioorganic & Medicinal Chemistry Letters","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.bmcl.2024.129622","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"129622"}}